0001193125-12-043879.txt : 20120207 0001193125-12-043879.hdr.sgml : 20120207 20120207165123 ACCESSION NUMBER: 0001193125-12-043879 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20120203 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120207 DATE AS OF CHANGE: 20120207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30489 FILM NUMBER: 12578469 BUSINESS ADDRESS: STREET 1: 10813 S. RIVER FRONT PARKWAY STREET 2: STE. 500 CITY: SOUTH JORDAN STATE: UT ZIP: 84095 BUSINESS PHONE: 858-312-8000 MAIL ADDRESS: STREET 1: 10813 S. RIVER FRONT PARKWAY STREET 2: STE. 500 CITY: SOUTH JORDAN STATE: UT ZIP: 84095 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 d296993d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 3, 2012

 

 

Lifevantage Corporation

(Exact name of registrant as specified in its charter)

 

 

 

Colorado   000-30489   90-0224471

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

9815 S. Monroe Street, Suite 100, Sandy, UT   84070
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (801) 432-9000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On February 3, 2012, in connection with its annual review of the management team’s compensation packages, the Company’s Board of Directors approved the recommendation of the Compensation Committee with respect to an increase of the annual base salary of Carrie E. McQueen, the Company’s Chief Financial Officer, Secretary and Treasurer to $288,500, effective as of January 16, 2012. The Board of Directors retains the discretion to further adjust Ms. McQueen’s annual base salary at any time. Ms. McQueen will also be eligible under the Company’s Annual Incentive Plan to earn a target performance bonus for fiscal year 2012 of $144,250, less all applicable withholdings and deductions. Such bonus opportunity shall be based on the achievement of Board specified performance goals and subject to the terms of the Company’s Annual Incentive Plan

Item 8.01. Other Events

On February 7, 2012, Lifevantage Corporation issued a press release announcing, among other things, that it will release financial results for the second quarter ended December 31, 2011, after the market closes on Tuesday, February 14, 2012. A copy of the press release announcing this news is attached as Exhibit 99.1 and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

 

  (d) Exhibits

 

Exhibit

Number

  

Description

99.1    Press release issued on February 7, 2012.

 

-2-


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: February 7, 2012     Lifevantage Corporation
    By:  

/s/ Carrie E. McQueen

      Carrie E. McQueen
      Chief Financial Officer, Secretary & Treasurer

 

-3-

EX-99.1 2 d296993dex991.htm PRESS RELEASE Press Release

Exhibit 99.1

 

LOGO

LifeVantage to Announce Fiscal Second Quarter 2012 Results on February 14, 2012

Salt Lake City, UT – February 7, 2012 – LifeVantage Corporation (OTCBB:LFVN), maker of Protandim®, the Nrf2 Synergizer™ patented dietary supplement, announced today it will release financial results for the second quarter ended December 31, 2011, after the market closes on Tuesday, February 14, 2012. The Company will hold an investor conference call at 2:30 p.m. Mountain time (4:30 p.m. Eastern time).

Investors interested in participating in the live call can dial (877) 604-9665 from the U.S. International callers can dial (719) 325-4886. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, February 16, 2012, by dialing (877) 870-5176 from the U.S., or (858) 384-5517 from international locations, and entering confirmation code 2407254.

There also will be a simultaneous, live webcast available on the Investor Relations section of the Company’s web site at http://investor.lifevantage.com/events.cfm. The webcast will be archived for 30 days.

To receive email alerts regarding LifeVantage’s upcoming investor events, stock information, SEC filings, or Company issued press releases, please visit the Company’s investor relations page and sign up for Email Subscription Alerts: http://investor.lifevantage.com/alerts.cfm.

About LifeVantage Corporation

LifeVantage, (OTCBB:LFVN), maker of Protandim®, the Nrf2 Synergizer™ patented dietary supplement, is a science based nutraceutical company. LifeVantage is dedicated to visionary science that looks to transform wellness and anti-aging internally and externally with products that dramatically reduce oxidative stress at the cellular level. The Company was founded in 2003 with headquarters in Salt Lake City, UT and operations in San Diego, CA. For more information, visit www.LifeVantage.com.

Investor Relations Contact:

Cindy England (801) 432-9036

Director of Investor Relations

-or-

John Mills (310) 954-1105

Senior Managing Director, ICR, LLC

GRAPHIC 3 g296993g19k54.jpg GRAPHIC begin 644 g296993g19k54.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`-P#L`P$1``(1`0,1`?_$`,(```$"!P$````````` M``````@)"@$"`P0%!@<``0`!!0$!```````````````%``(#!`8'`1````4# M`P,"`P4%!0(/`````0(#!`41!@<`$@@A$PDQ02(4"E%A<3(5@9%"(Q;PH=%2 M%[$:LC-#4R0T)365I=486#DZ$0`!`P($`P0'!@('!`L````!$0(#``0A,1(% M05$&87$B$X&1H=$R%`>QP4)28B/A%?!R@J*RXD.2,[,T\<)C@Y.CPR0E%C;_ MV@`,`P$``A$#$0`_`'^YAH`B']NNEWTCV52WF^[3P&FHGF09(E3@;[1#7A'* MO6N)"NJF90P!4*>OV:@ERS?- MP02RK26FM=;=#;W?VWS%F80" MJ:G$9?V>=9>;K/;+.X\FZ\TE!\+1Q[=7W4ISPYYC8>YSX0AN0>"'LZ]QY<,E M*Q4>:YH9*#F4'T(Z.QDF[Q@A(2:9#I.DQ#HJ/IH!?[/?;1/\MN!89"%&@J," MGVBCMCND.[1>;8`@8?&$X+P7A14E4J(@-/3^WOH9I>'G4GE\.?;1)I).D_$, MZB90`#[_`+NNG%KS\--?+'&4`YA$/0`]ZUU7/GB0`Z="XTYLD;A@JU$3# M["7]^K('?3'%_P"%*B!OM$O[](BO6EY^)%J43C4?\!TS3)V5[YL8PQJ.\/?U M_#2TR=E>>='VU(*OQ@7I00#\?6FI`PZ5=G4#KE)0P?"1]]5!.%:5#43W!K5X MU=`4+4G<$!H(E^[7C)&O*<:A;YBN5$#5JFJL8A!,7:(E#=M]=U/4H=?40]-. MD5H\.=2V_P"XNOV58M)EF_7QK2T(O.F121OU$_A%93?\`VIJ!)OTTWS6=M0[@_9_=KS]_]->>:WMJ M(&J'J%=3`(%=RISB4!'&O`8WN)=-:0ZFASUQ1*B!J^X>OVZ\<2'(.53)@M>$ M]/2@_P!_^S3FAQS2HW/:W-:D[GV_AZ#ZZ3V2:?VTU=M,\^,%"M>$Y@`P_#TI M2FH(&W9>DVC3V4^9XCBUM5:ID54,(UV^_H`_;JXYC1DM4HKB9Y.K2E5!.:G2 ME?P_?J)[7_@2KL(F`EQX>A:BGG;;Q&9_P MM]Z5@K=O6U+O!Z-JW##W$$>=-)\:%DF4D1FHL"HI%<':+JE3$X(F$`K4::;/ M:S6SO&$[Z\@NH;EJL*^JMA$1^T?WCIT1U-QI7`('ARK7+AO:U;2107NB>B;? M;NUSM6:\S(LHU%VNFD=8Z3=1VX1*H<$R"--.MK62]8?*&I"53AP6H[N\98O: MV3#4G+OH+O(5F->Q.!W)O*>.YMJ_?PV);R+"2T4[2=-V1M_/8>U[)B$Y%2)C[F"VI:[+IFG:9QE7LP=TW77306<=PQ!W4`* M:[3U-OVX],VORFUM)3'X-8\3=1*]_NKC73NVP=0W`FOW-#"4Q=I*!R(.7VT_ M\X#<1`5+\^YN+@52F+]@A7[M4X=FW;<)"UD M;GM8AP!&>&:!:MOWW;[0"29R.?AFWAV+6ZVQ>MKWI$H3=GW##W-$KD3.B_A) M)E)-S@?TJ9NN<4S4]C``ZAW"WOMN&B1CFO"!""ONJU:W5AN1\R-P3^L._@3S MK/J2""8IHF53,Y7`PMT"+-P67*3\YT$S*E,H1.OQ"'I35:SCN)P9I!X!G@1] MU-N9[>"1L8^)QPQ'OJJ"VZNT3"`"8-W\([:>@UZUKT_#3K@NC*5;@TO"YU*J MOVB%4$#&3H)CJ@8A$TB`(@8ZAU3I@4I:==/MUD&.5-G(C4FH)/FJY!41=MUD MP(*@JI+)*H]LHB!C]XAC)4`0Z_%J4Q70*!$)PP/N6J_S-KQ.(SQ'OK#FNNV@ M<@S-BZLDQ M/M'OK+H.2.``R8B;XA3^P=Q:B8`J(`:@!6H5"@ZAD=/$_P`J0>+L%/;%!<`7 M##XR$RM!=EZ M13);R.#PC[C]]:^M>UI$V MFR6?DN:C7`EX&(/NKRVNQ,U[B0F@\N'I6ME[Q>FT=XCM,&T0$-HA4#UW4$GW MA75KRUQ.`JLV[`:[FHY4@KX=[\FY?.?E78W9=;B0;P7,UNPM\DQ)&,WCXM:T MW)OE8P':A>VW(YZ&`H`6H?=H_O=H\1L\L$K&['/%1GZ*SNT[@#Q!=*I5$?;2%KYH."E,JR`FH4#BH&T?RB!J[A$*@!:=!J&JL,#VO4Y59D6^)"'@H/NJ]'=VMQ@TA.\>^KI)VFZ`11616`ICE.*"R2P)G((!L4% M%0X%,(#6GK3UU";FZA/[HP/Z:?HMI,B"AYU9.IJ,8)*+OY1DQ;(J%36LVN$0/B=AFWC M_:K-%<)G)O,!D@$ISE!0``3$3"IC@`"/2@?CJ!MPU/$JU[):JI:B]]7]0V;O M;;7]E*_[-/7C7J8)2/\`Y]'[^,\0_-)]&/'T>_;V=8)FSR->N(YZ@LI70=-74C2 MC@UF*+G(P9>FD:/I*+CN:X\:O+*&RNVQQENAS2N*XXIGE62Z)W*YNF(X.*'\HYM'`4\)J M`^@UUS2-S6/+5"+759&%S<0::)_5J7)<=MX#XJ+6_<$W``YS%-MGJD')/XU9 MR@6U)5P5)0[!5(ZA2G2#I]NNC_3"QBO6W+'H2`4"E?B`X5S'ZD7\]G)"Y@(: MK<4"?"XYFMEX\RTS,?3'W._F)-]+R:F(LCI+2,BY>-2VTS;_I-LLQQ.A2<`F"8C#.FG?CUX-< MQ>:C^^8[B5+.(9:R&D8-WG9W2K:R[L9(B35L*JY7;,K@B)UBF_,-`#78]VWG M:]LLO/W/4)2"-(*.^%1@HS&1XUR+:;6_NKP6=BTNCU`AVDN:I=CB`>.:Y4YK MR5R@Y$>$OQ.8_P`&Y%FD)3F-DVZ\ZT(*,W3,\XQP_?QQ;YM.1?N) M^V)FUY58C4;HM@S\ZR**K$`[A.P*9@$1"G00"'J!FV;]MS;J!)'EK2$Z,R[9 M*Q_FS($3[1G6_P!P@=+(S M$+%W'!KHF36*+&78-7K,XF;BHG\*1C`80$0`U0UFMQMG0R&"0'S&%"JXE3]R M5J]JO!-'Y@(##W)D*3/\RW)Z;XX\*+Q+8$DY1RSEJ3A,38N)'"(29KIO1Z#1 MNX9-TZ.E3LB'`ZFPIA(3XC``:(;'8F20.5-14.&>/ M`8_]-<@=^`''2D.L[9\Q^69<@J;GB60'N2+@6=JS`$*BE(FCPF3MR%*8"AM* MG0"E]--;U$[S$>P:5R!Q]N%>GIZ32H>-7:"GO]E97QQ9ZY-X3Y49,\:W,*]E M,GW'9]M(Y)P1E9VDF$]=^/\`OD26;2KU-NV%ZNR[0]Q0^XX;J&-UIJQ=V45] MMIWF(!@#])#L"[(8`8$J5YX&E%?R;6?Y6':GH7>%"@/?CP[L:3V0SIS4RQY& M.>'!_CS>%T6_*Y(OZQY>7R$]61=I82PW;[";CKI6M5=V9T2+EY=]*MC)E1*" MIQ)4/35J>TM;&%LDI;I:`1B<\!@O?Z*&V]Y<7\Q:T.53P]/#NH\9SZ?G"KV! M4FC;1.4K<1V^H`&@TFX_-R MM;(&^4QX<`7([#V9=J5H)[22TLS+$ID<""C=7!^H]HLCCM> M1CY_+-:6\&V)-,7^<,*93GI"[4$;"%P0TI*V^:65D7*@H-S&$1*J4X>^IVF/<&B-[ M4G(5,3WIR(XKZ*#0S/M;J0%W[+'D*0`.S$X'(ICWI2M7+CR06+Q\X,VSRVMY M`D_(Y5MRS$L+6=>9]L1^>/(YR/R^%_7PD6? M985QK=\M:EI61$R!"O8Z)4+"N88@R#8B_P`=!.```%$U0H!9V_#:A\G9`."J M?R@Y)S7#&@-OL74[=V61$WS4C9;M^,@]++1?<.8P).4U3EI3<`#2:+=K3=7- MBN8SY_#'C^DY\`M,DVRYV\%\;VF,=A]JA.-;=X,.4A\A<..47('(M[3SRTHK MD5EJYBR%U/%UG=K6:RBH.5;VZFL^4.8GZ:J95L5+<.TP[?4-5M\MH-4+8FD2 M.)P)..6/=F?15C:9KI[Y/,2IGV5Q?$>*>1_FRN6Z.0.7`/J']/;6Q9[\5N7^!EJ3')SQR M9YS(%WXR2"[KHP=D&[)6];)OVW8LHR4\GV;C=S1AE5V310";*&`3>H=-3[5N M]M0-NHE27N9L[:W)%',4OZ%=\08&-QP:J0J&,W,TQ`S!X><$(`*HN7JHVOX/0/R^G2GIZ?9 M30E/"G!*-\:1V\_]!\0'-6OI_1V/J^W3_6G&NMS].`T]:V`?\.M__"DK(]=* M.E+O3FD?_%CI%SZ0L1#&'-@"^AK\Q`!J![?HE]!U_9HY]38+<;JWRT0MQ0KQ M/;6(^G%U>",M>7)CP_4SLIXX!2E]*?V_;KEO^-=FF?.Z-6JO=30 M;ZN?X>/_`!+`.E,VW!_?9TSKIWTE;Y&XRDY:!_C;7+/JLX3;;$T8^/\`]-U; M=QE__,%<@_;B3(8_^<.M2W[P[ZB3/'YY/\)IEBTCH)H/%L?VMH0_I&USA>O+ M`.O:&'M@##[=P#L#``_?M#17ZJ0Z[@S9E&#^XE!?IA+H`C*IJ/\`CH4OJJKR MEWO/_%5N22JQ[=LO"D&,1'F3JR>,Y>9&2F"G4VUJN90R8AN"NB?TJI;I%-)5-PFB!B@0*"(UUG-RZ8CW#>9W3/``TN!3F0Q9,R_&*XL>W%C=M(Q;F990D MP=U/P\F07+1-PJD=PJJ$P4]FX#8Y-RJ\+.(<397CSKKWWQUE;"D6,HBLC(-G$6M-P=M&6 M2JL?X,,M7-,<59/C7DITH;+G#N^+IP;>+5\&R2=Q5 MSWRJR(S6DXFRHD558FRV*AQ;(SMY.VBSW_")OB.4YNGH($$/8 M.NL@6ZGN7%&UN[9-+BBA#2`LTU;Q7U#UE'8%*U_+H%>@\T60?O MM)QH7U*[]ICTR8X^H"C^S$BY>.9C^^EE\U9ELKC[B6^P$E.3S MHZJ:)Q;Q::BB2#+<("9S)&(!$R!4QS&``KK.;9`;T@8*>?`)B<*.[G>"R:7! M=/8GJQI""U>;/ERYN-_]0.'6!L:831)$Z1X\9>(9`G;[-VX(4&X_*'3!-(*^A0]1KJSNSTW&?0/&2T?W& M^\U4V>W_`/8L>X>$*?[Q%/14#;2#0M!*H=/84/@3(0VQ(I`#X0+VB@/3[=YAY-!^1SM!'Y! M5FL1X)Q,(%V@D;K7V'4]A-,Z^B/B`UCA0W:N.UFCDC`2B)3C1=40I6M!Z:ZT+2*YW]C+L` M1_)*-6&*CCAC7.W2O9T\?ECX_G.&."RCSXK>5N[\*<NAFY=+[9/*Z M3SFM!.6H(,O3[:O;9N^XQ1A@#L!GI[^RN]O?,_E239NXQ_XT>9JD?(M7#%\D M?#E]&(HS>)';NDSE_IZIBG14,`A[AJK:]*[/'*U[KAH1P_$.!'.K5SO>\/C< M(V2+I/X.*'LJU^GZ@6,;3R/;DO:KM*#O5NZ= M2RC9I+M&*IDR.6R0'$`&@B&JW7L>WNC9%MQC+2T@EK@Y4`XI3B.G\JE0IVZ5KT_+ZU^S6(3P:>RMVOB7MI'?Z@'_Z M?N:WY*?T;CZO<4!(H%_UJQIN'>8!`#`6M/M&@:VOT];JZRL0J>-^/_=/K)]; M_P#Y:[[F<%_U6)A33/Z?KRJ<3_'+87(VWN1T[>T?(Y/N?'$O;2EN66^N$KAO M"L+N0=@Z<-5DTT]H2!``VT`^[70NL.F+CY^GNX:%D+7-[&OKHP MZ^MFMQ7#];?=24'U(G)3'?+G@QPZL[UA<_S';HW)@7GM_">7?16 M\:2+$^E_N,H'*0_^C^1]J@AWD5*S#D2*$VB01K[=>GWZ&3/#^NY7'B^3_":+ MP1EG0S&X_#']HH1OI'`I>?+$`*X^*+M95)-1,4TEC?\`0B&'KU`H!T+U]-:/ MZF2_LZNUJ_[-9SZ=0.:YKA\.H\/UUN/U6O#B])M[ACF7:4$]>6]:EKO+`R2O M&IBZ&0%\&H!23F/R^T\Z,=>[ M<^1S)T4@<02/BRP3"B_\5OF=X`9,XYX\Q[R5N?#V'LXX^M.$M*X0R%#6W"V] MV0JX-)4%`$S1 M#]M4NG+_`&^RLG,W,1Z6M\.H``G42<3BOW5M&??/UX[<;9RQKBS%]EVKFB`N M&X4X>][WM"T(20AX-NY4!!`L*Y:QRZ,DN=80VC40$*]!T+DZ:WN"VUW1E9)R M\1[E*\:+6^\[!<71;#'`YN/Y>Q>&%.1;/=PTA;<"\MMFVC822A8Z8AH]HS0C M$21LJU([9$,U23(DV6[2M3D`H;3#K`W=K&*BN@V]W8NB%O&QK= M81%[\J;T9LO&*\:'E;NK.]XN5K?X_8F2FJR63.:.8[DR2DJ^()I%IC9BXF@/4MSX?Y6S`M'M*$(.P?;1[:+<3O&Y@>$E5[,1GE0]X4NBTL4 M^>SEI$Y>=M86[\QXDL57C_+71M392<7&NUDYZ'@UES(%!S*G$3F9BXMJ:3D'[9DU0 M,_1Y;-UCTFR%^+S.7'L)8<*YQ'=?.]1RS` M(/E](7D'9T8OC"$P^1?S!$5,GWRY-PR14B)!*GL_IZ\.VJ"@F-W#K%$=P@-` MVZS_`%-_R-O_`%?=6EZ;_P">E_K#[#2\YTP$4P*4H!W-IC#ZE*0?@`OXCT_; MK)L36YW(:V_XJPEW"7=2J0N#SZVUK_A[GXJV^6OETQC.298Z]SH'3VT;OP%KF]Q*5+97#8+YS"? M$L9[P%4>T5USS]PUQ7'XULKM[43D)-E`7ACN9NYE"HK/GB=DQL\U>W'\XDV. M)_E6D84QC@;IL]=4]EM?EWA@".+"G:!AA_3*KN[3&\RR!_C2CG$#(&*\D\<, M.79AR0A).Q7./+60AB0Z[4K=HLA%-4W,>X31$2-W*!BB!ZA7=75;=G7GF.75 MYA)/H3#U5/M5E:,0R:0`$QX%2O&@3\S?,/&O'/A)F:U7LDE(Y/RY8UQ6'CRQ MX]8CZXI9_*QYDWS_`/3FH@Y(QCFRX&%82B4P4T3V&SN9;N)T@?X6EQPX@(GK M515;?76;+.1L985>!GP7/.@`CN$MU

)W).QB_T_?EOY1(K"6])246B1$\U"S4 MD#,B[.2,01`/B'N;J&I0`K[GL)ED-S;:7P.=B,D/?D>/*I]NW:2UB\B4N#]* MA4QP2K#D=Y58GE1'SW%GQNMI/,V7+^C7\#)9Y37.W3B(/+RSLYC M@G90)^+OB-,YJ\1O/+BN=PXEIZ6SEF"WF$TJ)%5)B]89*%=J/&I]O1)U/-S% M*8!$?CZ#K6]57$%INENZ%S03;Z20>?/U4!V"*YFVA^MKG`7!.78*59\.O,R` MSAQKM;!]]2#>WN2/&MF.'YUT%,90D\N'#A1ZUO8[=(WMQQP5.[TX^H4JID')UC8JM&7OK( MMUV]:-KP;%Z_D966<-V2""#-JJ[4$/F%OYZH)(F$"E$!-3IZZSIM+^68,A&SM[NY4*;-M=]:;:4Z_9JLA5.-7.WA0L@VW_F?Y*3_IR'A/FD!_[/ M_/1S9F\"6&;.U^.=QSMQPET,FB`3TP>=A'<.9J\`7G;;IMP M<]RH"?=MVT"M0SUKU:VVO7W@AP>&C3J1$//3BO=6BN.B_F;1MLZY^$DKH[$R MU47^.O&7CJP/'<_\>3:]IYY8;VUYZVCW6JS3),`C/.5')US-?G#D540,?T!4 MN[[M"7;U_P#..WCRL'.<=*Y:@1FG!>5%V]/ILK=G\X^$-&K3^4C\*\4YUROQ M@^(#%7C$E\G&1F<:QD/Z@9I-"-$XTZ)B'3!-X[[GK)J?E'],*J].]+C8&AIF\XJ2NC2JE?S'^F-*G9)QK9 M.6K*G\<9!@F%R6C=D8XC)R'D6A7#)ZS$E<&$\Z7)B:&F7ZKE6 MTY.UT;NAFR)AWE:MC$GX`Y$TS"-.G0O3KKI%C]2'6A+I+,/>0!_O$Q''X#6/ MN.@(YV!GS*`$_P"FN?\`;HI.!WTW7%3B%?\`%Y6OVYY3.5_6^9%Q;B'Y<#-'ZE1?TM3.I-KZ"M M=NE,TDHE)7\"8G^T:<8),VR223=))-)%,@)$3`G\LB8`!03(0!#:F4H4*%>@ M:YOINS<><^=Y8JEO/TUMVV=I&08XVM1DXIK9 MU]1-\0,+%LW'MK(HL[> MLBVHNUHENF@">V-AV23%B4``X@04TB&$?6HFT'OI9+[T,19QP#FK&"$C::_'O'%VX\MFV6W95CY<+O^4_4+AFW7\M9U,F^5_F'V M_P`WX?R[>M2?J.:;;CMTS-7[NL.U<"$THG+BOHI1]+1P[@;Z.5%BTZ0SBJZE MU>Q*[/Q_X:V;Q\SER7SI;ER3LM.=F M_P"N8'%DEBMM!)E3-&*1!Q.FF<0!/9^:AMW2FB3-R++$V88,2"J M\BN2??0F3:1)??.EY7'!.83->'=0BWWET<<<,D8ND_)GP7.?:L>Y,R[/\`NFHW[).?]W5$1"NO#U.V M"=D]K;-:QIQ:'?$/RKIP'/"A\W3%SMT-Y M%"YH<6DL!U8`:<\.(Y4?@AAVK;193$.T@C4<,R798\TSK9IW#/!;FO%Q61IN MR\/YHCWC)FJQN19*->O'2!DB.$0$Z;A-8WPK5$IZ"`U#VZW'7F];6X6;V/\` M)<-0!*@<,`B^V@S[/;KU;H3-CTG20F?:J^Q*Y;R+R)P_\9?&G(]ZVI;U@8_5 M-;,A'VM:-H-F24_=MTN&CE*"A6C1%95TY67?+`6H5[=1'KZ:L;?%>;I?Q^:' MZ`\$G@$R3U>FJ5^++;["0,>UY?W5S?PBX&O##/!Z$E\CLW,+D7.-Z MWGF^YX1P)_F((;[F%9"(C5B*)IF37:QP$$_3X]WH'OYU/'?"')/)@Y_P`?7I>G'+D&""*"^1\9N2-"RVPQ MQ.M,Q(&;E>.E.Y\2@K!4H4IUJ$6W=12V3=$T?FMX*Y,,<,CS]E3W_3\%V[5$ MX1$\FKR[10S1/@LE+ZGXQSS!YP9RY%6?&N6J[6Q5CDMB'="U63.W1?E*_FQ7 M2.4FQ0!*&\HCZ5U>GZKAFC);'PUCB2=8FLZPWK)S%-+9:$3(9%F%`;J$(NV^)8/SGJ(FJ/ M30"VW(Q7/S-RWSB7%^85[MI_P"'NJT*F*DD!2@"H"``&P:E'I] MW7KI%[ERI+579]JE1_`H:B)4\J1J`$"@[5`VT'=T`?;UK7IKRO*E[9*#M4*` M=>YU`:@/M6OPTTJ50*D4"@!%B]FH]``HU-T_CK[:5*HBFG[J!3\2_P".E2J4 M$D_X50I[A4H_WUTJ53=M/_G`_>7_`!TJ5>,F4?\`C%0$/;T+TJ'O7KJ5KB/@ M%>J:E!)`!$2G+NKU^,!Z]/:NO2^1,04[J2U4`@>RG_!U&XJ:1KPIE'U4_#\H M:;7E45$43`&Y4H4&H5,4/8>GJ'MI4JK$)0M"*!Z4`:%,'J'7UTJ50,FD->X< M*B!@-U`H]?4?7I37K20X$9TJHD1;`/\`+5+6O^%2AM#[QKTIKS6[!!EE26O)I)%(`)J@)*`!:"4WPT^'K7KT]]>%S MEQ&-2ZW885PCD=`X`F\47*PY,2F-&&'WB*2%S.,O2=MQEAHH5-M%\\NQXS@V M;@PF'8J=0#%'T]-7["YN89P^WC<]X&0!7L5`21V94/OXHYV$3.$8[4^]*;\1 M/BGX!W;,O+HX#>34V$XM\\K$RG9:#I90ZCA-A#Q^048UBD0AP*"1 M`H0I0UK(>I+N$-9=[8V2YT_$YK@Y.P:3AQY5C[SIZ"Y=KAW)T,(.32U%[?$, M>%;UC;QN^-W"V7K-OCEGSZM3D9EYG.MU,ZF9`\'CR6OEZA M+2XJ=L$T4B&4`0"@#70Z7=MSGF+K.T?%(2,&!Y.66#?;5F/:-MA@T75XR1B9 MO+$S[74XT8-&:23?Y1VDHU^7+V2I&2.B8@D3V';"0YBD0[8%VE+\(%I360FC MN3=NGE=(&H06%453B5X\*U5J;)L`CM1&2$\32,D'+T&LD"90'X%`W>WH;\>E M>O32J>J8HF$]47($-4.X&PBFX`&HA03`):_;I4JN!+T$%#U#\`+I4JGZ4^ZG &]VE2K__9 ` end